High-barrier generic and first-generic products, developed with Korean manufacturing partners and commercialized in the United States.
Source products with high development and regulatory barriers, and clear US demand
Partner with Korean cGMP-certified manufacturers on formulation and scale-up
Lead FDA ANDA / 505(b)(2) filing, pricing, and regulatory strategy
Distribute through US partners under Arbormed Pharmaceuticals Inc.
Lead U.S. regulatory planning and submission strategy.
Build pricing, access and launch readiness for the U.S. market.
Connect products with specialized distribution and sales partners.
Four complex generic products are currently under contract, spanning injectable, hormonal, and iron-replacement therapies.
| Product | Indication | Manufacturing partner | Status |
|---|---|---|---|
| Sugammadex | Neuromuscular blockade reversal | Penmix | ANDA filed · Feb 2026 |
| Calcitonin Salmon | Severe osteoporosis | Etico (India) | US distribution contracted |
| Ferric Carboxymaltose | Iron deficiency anemia | Penmix | Clinical development |
| Otic Solution | Otitis media | US-based partner (PTS) | Exclusive US rights contracted |